SBIR/STTR Research Award

DNA Screening Assay for Human Herpes Virus

Award identifier 5d1a6e63a788bf612e83f657c67a8479c2a1a034fafb298803a166975b8ea231Awarding agency Department of Health and Human Services

Award amount

$48,317

Program and phase

SBIR · Phase I

Award year

1993

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Sra Technologies, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

Herpesvirus-6 (HHV-6) is a human pathogen that causes exanthem subitem (roseola) in children and appears to be associated with AIDS, tissue transplants and transplant rejection, various autoimmune diseases, lymphomas, Kaposi's sarcoma and other tumors, hepatitis, chronic fatigue syndrome, and several other diseases. Multiple strains of HHV-6 have been detected and categorized into two proposed groups. Unequivocal evidence is needed that HHV-6 is actually two or more closely related viruses, that each type is associated with different diseases, and that both types of HHV-6 can establish a latent infection in humans. The goal of the research is to develop reagents for assessing various HHV-6 strains in clinical samples. We have recently developed a novel, high-throughput assay for distinguishing between different strains of virus by a single base pair resolution method. We propose to apply this assay to samples of HHV-6 amplified from clinical samples by use of the polymerase chain reaction (PCR) method. Products will be detected with chemiluminescent probes, which are as sensitive as p32-labelled probes and more sensitive than fluorescent ones. In Phase I, we plan to adapt these methods to a rapid, economical assay for screening the two major strains of HHV-6 in clinical samples. In Phase II, we will refine and extend these procedures for distinguishing among the subtypes of HHV-6 that have been detected in infected clinical specimens of blood, saliva, urine, and tissue.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.